56 results about "Ototoxicity" patented technology

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, preferably of spiral ganglion neurons, by administration of a therapeutically effective amount of one or more molecules having erythropoietin activity selected from EPO, or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of EPO; a small molecule mimetic of EPO and an erythropoiesis stimulating agent. Also provided are improved compositions and methods for treatments of ototoxicity requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a molecule having erythropoietin activity.

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

The invention provides compounds, compositions and methods that can be used for the attenuation of damage to sensory hair cells and symptoms thereof. More particularly, the invention identifies drugs that can be used to protect sensory hair cells from ototoxic medications, noise-induced damage and age-related loss.

Provided herein are methods for preventing and / or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.

The invention relates to application of active octapeptide in the aspect of protecting sensory hair cells. According to the application of the active octapeptide in the aspect of protecting the sensory hair cells, the amino acid sequence of the octapeptide is as shown in SEQ ID NO.1. The application of the active octapeptide in the aspect of protecting the sensory hair cells has the advantages that active peptide containing 8 amino acid residues is used in sensory hair cell damage caused by aminoglycoside antibiotics; and after the detection, the condition that the peptide compound can play arole in protecting the sensory hair cells by decreasing the active oxygen content in a body is found for the first time, the damage of ototoxic drugs to the sensory hair cells is ameliorated, the toxic and side effects are small, and the active octapeptide is a hearing protection drug with a good development prospect and has a wide market prospect.

The invention discloses netilmicin sulfate inhalation powder and a preparation method thereof. The powder consists of the following raw materials:, namely netilmicin sulfate or a mixture of the netilmicin sulfate and an amino acid glidant, wherein the weight ratio of the netilmicin sulfate to the amino acid glidant is 10-30:1. The method has the advantages that the preparation technology is simple, no organic solvent or preservative is used in the preparation process, the flowability of the prepared powder is greatgood, the deposit rate at effective parts is high, and the problems that the netilmicin sulfate has high water solubility and cannot be absorbed when isbeing orally taken are solved; and meanwhile, as the inhalation powder is used as a medicine performing a local function, the dosage of administration is obviously reduced, and the occurrence rate of side effects related to an aminoglycoside dosage, such as ototoxicity and renal toxicity is reduced.

A method of limiting noise damage to an individual includes receiving, by an ototoxicity application stored in a non-transitory memory and executed on a processor, a first individual exposure level toa first ototoxic condition in an area, correlating the first individual exposure level to an ototoxic effect, determining a noise level threshold based on the correlating, receiving a noise level exposure in the area, comparing the noise level threshold with the noise level exposure, and sending an alert when the noise level exposure exceeds the noise level threshold. The noise level threshold isbelow a standard noise level threshold.

Compositions comprising a flavan-3-ol, a flavonoid, and a fatty acid have been demonstrated to mitigate the oxidative damage arising from mitochondrial dysfunction. In preferred embodiments, the composition comprises epicatechin, quercetin, and cicosapentaenoic acid (EPA) ethyl ester. The disorders to be treated include neurodegenerative disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and multiple sclerosis (MS); neurological damage due to stroke; and ototoxicity arising from chemotherapy with cisplatin.

Ototoxic side-effects have either limited the application of an important group of antibiotics, aminoglycoside antibiotics, or have added further burden to those who have to resort to platinum-containing antineoplastic agents to treat life-threatening tumors. The present invention discloses pharmaceutical compositions that prevent or treat the ototoxic side-effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents. The otoprotective compositions disclosed herein can also be used to treat noise induced hearing loss.

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

The present invention relates to the use of a compound for the preparation of a medicament for the prevention and / or treatment of induced cytotoxicity, such as nephrotoxicity and ototoxicity, in particular said cytotoxicity is induced as a result of drug treatment. In a preferred embodiment, the compound has at least two nitrogen atoms, more preferably at least two amino groups. The compound of the present invention can block the binding of cytotoxic compounds to megalin receptors, thereby inhibiting the uptake of the cytotoxic compounds into cells. The present invention also relates to novel compounds for use in said treatment, as well as methods of reducing the cytotoxicity of cytotoxic compounds, more particularly gentamicin.

A novel method of preventing or reducing ototoxicity in vertebrates undergoing treatment with therapeutically effective amounts of platinum-based chemotherapeutic agents such as cisplatin or aminoglycoside antibiotics is disclosed herein. The method(s) comprise administering an effective amount of an otoprotective agent comprising Dihexa prior to, concomitantly with, or subsequently to administration of the platinum-based chemotherapeutic agent or aminoglycoside antibiotic.

The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.

The invention provides an application of tetrahydropalmatine in preparation of medicine for resisting cisplatin toxicity. The toxicity comprises kidney toxicity, ototoxicity and neurotoxicity. The research shows that tetrahydropalmatine has inhibition effect for OCT2 and MATE1, can antagonize the cytotoxicity caused by cisplatin, and obtains good verification for primary culture of a renal tubular epithelial cell model. By taking (-)-THP as a representative, the research finds that tetrahydropalmatine has good protection effect for mice kidney damage caused by cisplatin, so that tetrahydropalmatine and cisplatin are combined, accumulation of cisplatin at kidney, cochlear cells and dorsal root ganglion is reduced, so that the expection result for preventing or reducing cisplatin toxicity can be achieved. The application develops the novel purpose of the tetrahydropalmatine, because that OCT2 is highly expressed by kidney, cochlear cells and dorsal root ganglion, expression of OCT2 is lacked on tumor cells, cisplatin has certain passive permeability, so that tetrahydropalmatine and cisplatin are combined, toxicity due to cisplatin is decreased, and cisplatin antineoplastic effect is not reduced.

The present invention relates to the use of neurotrophins in the treatment of hearing disorders related to hearing loss using the transtympanic route of administration, in particular in the treatment of sudden deafness, blast-induced hearing loss, ototoxicity, ARHL (age related hearing loss) and noise damage. The invention further relates to the use of compositions containing neurotrophins, in particular NGF, in the treatment of hearing disorders.

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

The present invention relates to novel aminoalkyl-oxazole and aminoalkyl-thiazole carboxylic acid amides that stimulate the endogenous regeneration of terminally differentiated cells in highly specialized organs, tissues and sensory epithelia in mammals in situ. The claimed low-molecular-weight compounds are able to induce corresponding cell biological changes such as dedifferentiation, proliferation and the subsequent terminal redifferentiation of cells of the normally post-mitotic tissue. The invention in particular relates to compounds with which a de novo formation of hair sensory cells in the organ of Corti can be obtained by inducing cell separation of supporting cells of the inner ear and hearing can be restored after hair cell loss. The compounds according to the invention for the first time enable a causal treatment of inner ear hardness of hearing caused, for example, by noise, ototoxic substances, symptoms of old age or genetic causes on the basis of regenerative biology. The invention further relates to methods for producing the compounds according to the invention, to the formulation (1) (2) thereof as pharmaceutical preparations and to the use thereof for producing pharmaceuticals for regenerative medicine.

The invention discloses an application of an Htra2 gene expression inhibitor in prevention of acquired sensorineural deafness. The Htra2 gene expression inhibitor is used for preventing ototoxic deafness caused by aminoglycoside antibiotics. The invention also provides a CRISPR / Cas9 gene editing system for preventing the acquired sensorineural deafness, and the CRISPR / Cas9 gene editing system is used for targeting and knocking out the Htra2 gene. The invention proves that the AAV-CRISPR / Cas9-Htra2 gene editing system inner ear microinjection can be used for safely and effectively preventing the ototoxic deafness caused by the aminoglycoside antibiotics.

The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and / or treatment of induced cell toxicity, such as nephewrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment, the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of docking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds.

Loss of bilateral vestibular function is a chronic disease that may result from ototoxic, infectious, traumatic, autoimmune, or congenital causes. The purpose of the present invention is to improve the effectiveness of a vibrotactile feedback device. The present invention provides a vibrotactile feedback device for arrangement to a human body, comprising: a sensor arranged to sense a current posture of the human body relative to an environment; a haptic actuator arranged to allow the human body to perceive a posture deviation; an elongate carrier for holding the haptic actuator and the sensor in haptic communication with the human body and for holding the haptic actuator and the sensor substantially fixed relative to the human body; and a processing unit configured to: receive the current pose from the sensor; determining the posture deviation based on comparing the desired posture of the human body with the current posture; and transmitting an actuation signal to one or more of the haptic actuators based on the attitude deviation; wherein the haptic actuator is arranged to the carrier such that the haptic actuator is substantially arranged in a reference plane when the carrier is used; wherein the reference surface is functionally perpendicular to a central axis of a torso of the human body, and the reference surface intersects the torso to define a circumference to which the haptic actuators are arranged; and wherein the carrier comprises a stretchable material such that the relative distance between the haptic actuators and / or between the haptic actuators and the sensor is maintained irrespective of the length of the circumference.

A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss.

The invention discloses application of deferiprone in inhibition of ototoxicity of aminoglycoside drugs, and belongs to the field of drug-induced deafness. The invention discloses an application of deferiprone (DFP) in protection of hearing loss caused by aminoglycoside drugs. The DFP is the only oral active iron chelating agent and is clinically used for treating blood transfusion iron overload in thalassemia. According to the application, aminoglycoside drug damage, hair-like cells HEI-OC1 and mitochondrial autophagy occurrence levels in in-vitro cultured cochlea tissues are firstly researched, the protective effect of the DFP on the hair cells by regulating mitochondrial autophagy on the in-vitro cultured cochlea tissues is researched, and finally, the protective effect of the DFP on mouse hearing loss caused by aminoglycoside drugs is researched. A new thought is provided for treating drug-induced deafness, and a new target is provided for clinically helping a patient to recover and reconstruct an auditory function.

Provided herein are methods for preventing and / or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

A method of treating inner ear hardness of hearing and restoring hearing of humans and animals after damage and loss of sensory hair cells in an organ of Corti based on regeneration biology includes administering a therapeutically effective amount of a compound including aminoalkyloxazole and aminoalkylthiazole carboxylic acid amides, or a pharmaceutically acceptable salt, a stereoisomer, a stereoisomer mixture, a tautomer or a prodrug compound thereof, directly or indirectly to damaged tissue structures in a cochlea, optionally, by transtympanal injection into a middle ear, by application to a round or oval window of an inner ear or by injection into the inner ear.

The present invention provides a method of attenuating side effects caused by aminoglycosides by administering aminoguanidine either before or during the treatment with the aminoglycoside. The invention also provides compositions and kits for use in the treatment of infections that use aminoglycosides that can cause side effects such as nephrotoxicity and ototoxicity.